A Study of PHN-012 in Patients With Advanced Solid Tumors

Part of paid clinical trials in Los Angeles, California.

Sponsor
Pheon Therapeutics
Study ID
NCT07127874
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • PHN-012 — DRUG
    PHN-012 is an ADC

Study Details

This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.

Key Dates

Start date
Sep 23, 2025
Status verified
Jun 2026
Primary completion
Sep 30, 2027
Completion
May 31, 2028

Study Design

Enrollment
165 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Phase 1a and Phase 1b
    PHN-012 is administered intravenously

Primary Outcome Measure

Incidence of dose limiting toxicities (Phase 1a) [ Time Frame: 12 months ]

Central Contacts

Locations (11)

FacilityCityStateZIPSite coordinators
PHN-012-001 SiteLos AngelesCalifornia90033-
PHN-012-001 SiteSan DiegoCalifornia92037-
PHN-012-001 SiteWashington D.C.District of Columbia20007-
PHN-012-001 SiteBostonMassachusetts02114-
PHN-012-001 SiteSt LouisMissouri63108-
PHN-012-001 SiteDurhamNorth Carolina27710-
PHN-012-001 SitePortlandOregon97239-
PHN-012-001 SiteNashvilleTennessee37203-
PHN-012-001 SiteHoustonTexas77030-
PHN-012-001 SiteSan AntonioTexas78229-
PHN-012-001 SiteFairfaxVirginia22031-

Find similar trials in Los Angeles, CA

By condition
Colorectal cancerPancreatic cancer
By specialty
OncologyGI oncology
By research site
PHN-012-001 Site· Los Angeles, CAPHN-012-001 Site· San Diego, CAPHN-012-001 Site· Washington D.C., DCPHN-012-001 Site· Boston, MAPHN-012-001 Site· St Louis, MOPHN-012-001 Site· Durham, NC

Related Studies